SecBot SecBot
PRESS-RELEASE ·Filed Jun 12, 2026

BCRX

BioCryst Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a routine medical conference data dump with no financial catalysts. ORLADEYO's core commercial story remains unchanged. Watch for Phase 3 navenibart (ALPHA-ORBIT) top-line data as the next binary catalyst, timing not stated in this release. No actionable trade signal from this filing alone.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.70
T+0 close · Jun 12, 2026 · via day close
Latest settled
+4.20%
T+60 · $9.07
Vs SPY
+0.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $8.70entry
  2. T+1 · 5mo ago +4.14%α +2.37% · $9.06
  3. T+5 · 5mo ago +3.33%α +2.66% · $8.99
  4. T+20 · 4mo ago +20.11%α +18.34% · $10.45
  5. T+60 · 2mo ago +4.20%α +0.93% · $9.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained HAE attack reductions and a post hoc analysis of Phase 1b/2 navenibart data supporting ongoing Phase 3 evaluation. The press release contains no new revenue, earnings, or financial guidance, it is a clinical data update with routine positive framing.

Key Facts

  • ORLADEYO 48-week data in pediatric HAE (APeX-P; n=29) showed median adjusted attack rate fell from 0.691/month (SOC) to 0.169/month on treatment.
  • Attacks requiring professional care dropped from 22 (SOC 12wk) to 3 (first 12wk on ORLADEYO), reaching 0 in weeks 37-48.
  • Phase 1b/2 ALPHA-STAR post hoc analysis (navenibart, n=29) showed consistent HAE attack reductions across baseline attack rate, BMI, and age subgroups.
  • No severe or serious treatment-emergent adverse events reported for navenibart; most common TEAEs were headache, nasopharyngitis, and UTI.
  • Multiple real-world evidence posters demonstrate ORLADEYO reduces healthcare utilization and improves patient satisfaction.
  • No financial data, revenue, EPS, guidance, or material commercial updates were provided in this press release.

Financial Impact

No direct financial impact disclosed; clinical data updates support ongoing commercialization and pipeline value but do not change near-term revenue outlook for ORLADEYO.

clinical trial datapipeline progress

Risk Factors

  • No new commercial metrics or revenue guidance were provided, upside from this data is speculative.
  • Navenibart Phase 3 results remain pending; could fail to replicate Phase 1b/2 findings in a larger, longer trial.
  • Small n (29) and open-label design of APeX-P and ALPHA-STAR limit conclusiveness of these data.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3310979

Track record

20 reports on BCRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026